Aggregator

A new museum exhibit in St. Charles highlights the Battle of Fort San Carlos, also known as the Battle of St. Louis.

Pho No 🏴‍☠️ JW Tue, 05/17/2022 - 13:27

One of our favorite joints is closing.

I was introduced to Pho Grand through Zipatoni.

We always seemed to pick Tuesday to go, tho.

 

Their website/ordering is my favorite.

No bs, here's the menu in readable text and click on the phone number to automagically call.

Their process is beauty.

Usually 20 min for a pickup.

 

NEVER had a bad experience in the 28 years I've been going.

Tags Pho Grand Captains Blog

This story was originally published by Investigate Midwest.  Lawyers for Tyson Foods, one of America’s largest meatpacking companies, drafted an early version of a 2020 executive order that allowed plants to continue operating during the COVID-19 pandemic, a new Congressional report based on company emails shows. It’s been reported that the meatpacking industry wrote a draft […]

The post Tyson Foods wrote draft of Trump order keeping meatpacking plants open during pandemic appeared first on Missouri Independent.

Gabriela Ramirez-Arellano and her husband and chef, Victor "Hugo" Arellano-Guzman, wrote, "This is not goodbye, but rather, hasta mañana."

ALTON – Although Alton Memorial Hospital was unable to hold its annual Employee Awards Banquet again this year because of the pandemic, the hospital was still able to honor several of its top staff members for their 2021 accomplishments during the recent Health Care Week. Among the awards handed out was the Virginia Ilch Team Quality Award. The ”Promoting Vaginal Births” team was the winner for its part in a 2021 quality initiative as a part of the Illinois Perinatal Quality Collaborative. “The aim was to support vaginal births and reduce primary cesarean sections to reach the Healthy People goal for a low-risk cesarean section target rate of 24.7 percent by December 2021,” said Debbie Turpin, chief nurse executive at Alton Memorial. AMH had a C-section rate of 22.5 percent in 2020. A team of nurses and physicians led the 2021 efforts for AMH, which included: Educating physicians and nurses on ACOG/SMFM labor management guidelines and labor support

Continue Reading

by Charles Ornstein

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published.

Twelve years ago, ProPublica set out to build a first-of-its-kind tool that would allow users, with a single search, to see whether their doctors were receiving money from an array of pharmaceutical companies.

Dollars for Docs generated a huge rush of interest. Readers searched the database tens of millions of times to see if their doctors had financial ties to the companies that made the drugs they prescribed. Law enforcement officials used it to investigate drug company marketing, drug companies looked up their competitors and doctors searched for themselves.

A trove of recently released documents offers the public an unvarnished look inside those relationships from the perspective of drug companies themselves. The material shows company officials worked to deflect the media scrutiny even as they sought to take advantage of relationships that they had built with doctors they were paying significant sums of money.

The documents were published online by the University of California San Francisco and Johns Hopkins University and became available as a result of drugmakers settling lawsuits against them for their role in the opioid crisis. These are exactly the kinds of documents we wanted to see when we started working on the Dollars for Docs series in 2010, but of course, no one was willing to show them to us.

Reading them should give patients even more pause about the financial entanglements their doctors have with the drug industry and spur them to ask questions (we have some ideas about specifics below).

The Washington Post mined the records and found that more than a quarter of the 239 medical professionals ranked as top prescribers by opioid maker Mallinckrodt Pharmaceuticals in 2013 “were later convicted of crimes related to their medical practices, had their medical licenses suspended or revoked, or paid state or federal fines after being accused of wrongdoing.” The article was replete with examples of doctors whose problems were well known but who were targeted anyway by sales representatives.

This was a familiar finding. Back in 2010, we found that hundreds of doctors paid by drug companies to promote their drugs had been accused of professional misconduct, were disciplined by state boards or lacked credentials as researchers or specialists.

The document trove included some mentions of our earlier work.

Among them: a 2010 email from a senior director of global compliance at Cephalon Inc., a small drug company that was subsequently acquired by Teva Pharmaceuticals.

In the message, the director notes that what ProPublica found — Cephalon had paid doctors who had been sanctioned by their states to deliver promotional talks on its behalf — was, indeed, true, and that the company was undertaking a review of all of its doctors in light of our findings.

(Screenshot by ProPublica)

Another document included a list of those doctors.

And there’s a 2017 presentation from an official at Mallinckrodt about the state of transparency around payments to doctors. It called ProPublica the “most thorough and vocal media source re: Open Payments data. Their analyses and searchable database are likely the go-to place for anyone wanting to do a comparison of companies and physicians.”

(Screenshot by ProPublica)

Our Dollars for Docs data often was picked up by news outlets across the country, including WNBC-TV in New York City. In one document, a spokesperson for the company Covidien was happy that the reporter had not asked about Exalgo, a new opioid made by the company. “Based on our conversation, I do not believe that the reporter is aware of Exalgo — and I am certainly not planning to make him aware,” she wrote in 2013.

The document trove also shows firsthand how drug companies targeted doctors and used information purchased from data brokers to rank them and gain insight on how many of their drugs each doctor prescribed each week.

When we first started working on our stories, we were very eager to see what pharma drug reps knew about the prescribing practices of doctors. So we asked a company then called IMS Health, which purchased data from pharmacies on which drugs each doctor prescribed and then sold it to the drug companies, if it would sell that data to us. IMS, now known as IQVIA, told us we could not buy the data at any cost.

The document trove includes a number of samples of what that data looks like and makes clear why the industry was so reluctant to have it come into public view.

The following chart was put together for Covidien about Exalgo. For every doctor in the Las Vegas region, it shows their prescribing, by week, of the drug and notes whether they are a “target.”

(Screenshot by ProPublica)

Documents then show how such information was used when meeting with doctors. In this email, a Covidien drug rep brags about how she was able to turn a doctor’s office staff into allies who would feed her information and talk up the company’s drugs to the doctor. “The nurse got very excited ... and wanted to know all about the product, the coverage, how to use it, etc. She even took the liberty of detailing the doctor when he walked into to (sic) lunch as well.”

(Screenshot by ProPublica)

The documents also showed how closely Covidien measured the performance of drug reps in getting doctors to prescribe their drugs.

(Screenshot by ProPublica)

Covidien spun off Mallinckrodt in 2013 as a specialty pharmaceutical company, managing drugs such as Exalgo. (Mallinckrodt stopped promoting Exalgo in 2015 and no longer sells it.) Covidien focused on medical devices and was acquired by Medtronic.

In 2020, Mallinckrodt agreed to pay $1.6 billion to settle with states and the federal government for its role in the opioid crisis. That figure has since grown to $1.725 billion. In response to a request for comment, a spokesperson for the company sent a statement identical to one it had sent to the Post: “While Mallinckrodt does not agree with the allegations regarding decade-old issues, it has spent the past three years negotiating a comprehensive, complete and final settlement that resolves the opioid litigation against it, provides $1.725 billion to a trust serving affected communities, and allows Mallinckrodt to continue to serve patients with critical health needs under an independently monitored compliance program.”

This year, Mallinckrodt also agreed to pay $260 million to resolve allegations that it underpaid rebates to the Medicaid program and paid illegal kickbacks related to another of its drugs, H.P. Acthar Gel. As it happens, ProPublica has also written about that drug, raising questions about the public spending on it in light of questions about its efficacy.

We stopped updating our Dollars for Docs tool in 2019 because the government’s Open Payments database is robust and refreshed annually and has gotten better with time.

Still, searching through these documents reinforced my view of how important it is for patients to know about their doctors’ relationships with drug companies and talk directly to their doctors about the drugs they are prescribed.

Here are some of the questions you may want to ask:

• What type of work do you do with these companies?
• Have you prescribed me any drugs that are manufactured by companies you’ve taken payments from?
• Are there non-drug alternatives that I may want to consider first?
• Are there less expensive generic alternatives to the drugs you have prescribed?
• What devices have you used in my care that are manufactured by companies you’ve taken payments from?

Have you used Dollars for Docs or Open Payments? What have you found? I’d love to hear your story.

"I think this group of young Latinos gives St. Louis hope in regards to the workforce issues that we currently have, but I still believe that there’s some work to be done so that people will stay here."

Is there an alien force on a mission to explore strange new worlds — like ours? UFO enthusiasts are hoping some of the truth they believe is out there could be revealed Tuesday in Washington, D.C.

The estimate cost of the Affton and north St. Louis County stations has risen from about $13 million to $38 million.

A Chesterfield-based health care billing company has acquired a New Jersey-based provider of medical billing and coding services.

Several years ago you might recall that a bunch of eBay executives were busted waging a bizarre harassment campaign against a blogging couple who had been critical of the company. David and Ina Steiner, the folks behind Ecommerce Bytes, had occasionally (and fairly tamely) criticized some eBay business practices. Instead of addressing those practices, numerous […]

ST. LOUIS - It's Free Trip Tuesday brought to you by Ryan Kelley, The Home Loan Expert. On Tuesday, May 17, you could win a trip for six to Yogi Bear's Jellystone Park Resort. The winner will get a four-night stay in a two-bedroom cottage, with full kitchen and bath. They will also get unlimited use of the pool and [...]

"Takera was goofy and silly and loved to hang out with her cousin. She was extremely respectful."

Larder & Cupboard offers handcrafted jams and jellies in a bevy of flavors, ranging from blood orange-IPA to bourbon-peach.

David Hoffmann and his wife will still serve as advisors for the Augusta project, which calls for a hotel, 12-hole golf course and other amenities.

Family of the 16-year-old girl say an unknown man shot the teen in the stomach while inside of a vehicle.

Composer-vocalist Annika Socolofsky will present reimagined lullabies with seven members of the St. Louis Symphony Orchestra this week at the Pulitzer Art Foundation. She turns folk melodies into “feminist rager-lullabies” that convey messages she describes as full of beauty, passion and rage.

The online platform spans 56 searchable options, including a red barn, a yurt, a scenic spot along a golf course, and more.